These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37852849)

  • 1. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
    Lu K; Woodward BD; Boys J; Onaitis M; Husain H
    Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
    [No Abstract]   [Full Text] [Related]  

  • 2. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
    Romero D
    Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
    [No Abstract]   [Full Text] [Related]  

  • 3. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    Wang VE; Gainor JF
    JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
    [No Abstract]   [Full Text] [Related]  

  • 4. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
    Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Moik F; Riedl JM; Ay C
    Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
    [No Abstract]   [Full Text] [Related]  

  • 7. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
    Remon J; Saw SPL; Cortiula F; Singh PK; Menis J; Mountzios G; Hendriks LEL
    J Thorac Oncol; 2024 Feb; 19(2):199-215. PubMed ID: 37783386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lazarus effect in a patient initially empirically treated with osimertinib for
    Bhatia S; Cortez MG; Lessans S; Iams WT
    Oncotarget; 2024 Jan; 15():27-30. PubMed ID: 38227738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired Resistance to Osimertinib in
    Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
    Passaro A; Wang J; Shah S; Bauml JM; Campelo RG; Cho BC
    Ann Oncol; 2024 Mar; 35(3):328-329. PubMed ID: 38029840
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    Lim SM; Lee JB; Cho BC
    J Thorac Oncol; 2024 Mar; 19(3):376-379. PubMed ID: 38453325
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    Chen LN; Lee ATM; Nagasaka M; Ou SI
    J Thorac Oncol; 2024 Mar; 19(3):380-384. PubMed ID: 38453326
    [No Abstract]   [Full Text] [Related]  

  • 13. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
    Yu Z; Xu F; Zou J
    Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.
    Al-Obeidi E; Kelly K; Gandara DR; Riess JW
    JCO Precis Oncol; 2024 Apr; 8():e2300677. PubMed ID: 38603654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.
    Bennett P; Finall A; Medeiros F; Gerrard G; Taniere P
    Eur J Cancer; 2022 Oct; 174():315-317. PubMed ID: 35934607
    [No Abstract]   [Full Text] [Related]  

  • 16. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
    Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    van Waalwijk van Doorn-Khosrovani SB; Badrising SK; Burgers S
    N Engl J Med; 2024 Feb; 390(5):478. PubMed ID: 38294983
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
    Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
    Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
    Rotow JK; Lee JK; Madison RW; Oxnard GR; Jänne PA; Schrock AB
    J Thorac Oncol; 2024 Feb; 19(2):227-239. PubMed ID: 37806383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    Planchard D; Jänne PA; Kobayashi K
    N Engl J Med; 2024 Feb; 390(5):478-479. PubMed ID: 38294984
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.